mRNA vaccines represent the largest sub‑type within the Approved COVID‑19 Vaccines market, accounting for roughly 45 % of global doses administered. Their rapid design cycle and high efficacy rates have driven widespread procurement by both high‑income and emerging economies, directly expanding market volume. Viral‑vector vaccines follow, contributing approximately 30 % of the market. Their storage requirements are less stringent than mRNA products, enabling broader distribution in regions with limited cold‑chain infrastructure, thereby adding a distinct revenue stream. Protein‑subunit vaccines occupy about 15 % of the market; they are characterized by conventional manufacturing processes and a favorable safety profile, which supports adoption in populations with heightened safety concerns. Inactivated virus vaccines make up the remaining 10 %, primarily serving markets with established regulatory pathways for traditional vaccine platforms. Collectively, these type categories delineate the market taxonomy, with each sub‑type influencing total market size through differential manufacturing costs, distribution logistics, and regulatory acceptance. Future pipeline additions, such as next‑generation mRNA constructs, are projected to shift these shares, underscoring the dynamic nature of the market.
